|
Sponsored Research and License Agreements (Details) (USD $)
|
9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 6 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 6 Months Ended | 9 Months Ended | 1 Months Ended | 3 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
|
Apr. 30, 2010
Collaborations
AstraZeneca
|
Sep. 30, 2012
Collaborations
AstraZeneca
item
|
Apr. 30, 2010
Collaborations
AstraZeneca
Single unit of accounting
item
|
Sep. 30, 2010
Collaborations
AstraZeneca
Single unit of accounting
|
Sep. 30, 2010
Collaborations
AstraZeneca
Milestone achieved
|
Sep. 29, 2010
Collaborations
AstraZeneca
Specified events
|
Sep. 29, 2010
Collaborations
AstraZeneca
Development event
|
Sep. 29, 2010
Collaborations
AstraZeneca
Regulatory event
|
Sep. 29, 2010
Collaborations
AstraZeneca
Product launch event
|
Sep. 29, 2010
Collaborations
AstraZeneca
Specified sales levels
|
Sep. 30, 2012
Collaborations
Other Agreements
Specified events
|
Sep. 30, 2012
Collaborations
Other Agreements
Development event
|
Sep. 30, 2012
Collaborations
Other Agreements
Regulatory event
|
Sep. 30, 2012
Collaborations
Other Agreements
Product launch event
|
Aug. 31, 2002
Collaborations
Daiichi Sankyo
|
Sep. 30, 2012
Collaborations
Daiichi Sankyo
|
Jan. 31, 2012
Collaborations
Daiichi Sankyo
Milestone achieved
|
Jul. 31, 2011
Collaborations
Merck Serono
|
Sep. 30, 2011
Collaborations
Merck Serono
|
Aug. 31, 2011
Collaborations
BerGenBio
|
Jun. 30, 2012
Collaborations
BerGenBio
|
Sep. 30, 2011
Collaborations
BerGenBio
|
Jul. 31, 2012
Collaborations
R256
|
Jun. 30, 2012
Collaborations
R256
|
|
| Collaborations | |||||||||||||||||||||||||
| Number of significant active collaborations | 1 | ||||||||||||||||||||||||
| Upfront fee received | $ 100,000,000 | $ 1,000,000 | |||||||||||||||||||||||
| Number of units of accounting | 1 | ||||||||||||||||||||||||
| Revenue recognized | 100,000,000 | 25,000,000 | 4,300,000 | 500,000 | 500,000 | 1,000,000 | |||||||||||||||||||
| Maximum amount of payments receivable | 320,000,000 | 25,000,000 | 100,000,000 | 195,000,000 | 800,000,000 | ||||||||||||||||||||
| Potential amount of payments receivable | 160,000,000 | 68,900,000 | 53,600,000 | 37,500,000 | |||||||||||||||||||||
| Cumulative amount of payments earned under collaborative arrangement | 6,500,000 | ||||||||||||||||||||||||
| Period for making upfront payment | 12 months | ||||||||||||||||||||||||
| Collaborative payment earned | 750,000 | 500,000 | |||||||||||||||||||||||
| Uncured breach period | 60 days | ||||||||||||||||||||||||
| Notice period for termination of agreement without cause | 180 days | ||||||||||||||||||||||||
| Notice period for termination of agreement due to change of control | 30 days | ||||||||||||||||||||||||
| Period of collaboration in research phase | 3 years | ||||||||||||||||||||||||
| Final payment received | $ 4,300,000 | ||||||||||||||||||||||||